Story perspectives

Japan Advances Regenerative Medicine for Heart and Parkinson's Diseases

2/19/2026

Summary

Story summary

On February 19, 2026, Japanese government experts endorsed projects for regenerative medicine targeting heart diseases and Parkinson’s, pending Health Ministry approval.
These initiatives could result in the first commercially available medical products using induced Pluripotent Stem (iPS) cells.
Nobel Prize winner Shinya Yamanaka, who pioneered iPS research, supports these projects.
The proposals include ReHeart by Cuorips, aimed at restoring heart function, and Amchepry by Sumitomo Pharma and Racthera for Parkinson’s patients.
iPS cells are generated by reverting specialized cells to a juvenile state, enabling various medical applications.

1 of 1

Story summary

On February 19, 2026, Japanese government experts endorsed projects for regenerative medicine targeting heart diseases and Parkinson’s, pending Health Ministry approval.
These initiatives could result in the first commercially available medical products using induced Pluripotent Stem (iPS) cells.
Nobel Prize winner Shinya Yamanaka, who pioneered iPS research, supports these projects.
The proposals include ReHeart by Cuorips, aimed at restoring heart function, and Amchepry by Sumitomo Pharma and Racthera for Parkinson’s patients.
iPS cells are generated by reverting specialized cells to a juvenile state, enabling various medical applications.